Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors by Ron H J Mathijssen, Arjen Joosse, Daniel Bos, Esther Oomen-De Hoop, Jorie Versmissen, Astrid A M van der Veldt, Daan C H van Dorst, Tom J J Uyl, Timy Andrawes, Alexander HJ Danser

Get full text

Early prediction of menopausal status after chemotherapy in women with early breast cancer in order to optimize adjuvant endocrine therapy by Charissa van Zwol-Janssens, Mandy M. van Rosmalen, Esther Oomen-de Hoop, Jan C. Drooger, Annemieke van der Padt-Pruijsten, Hanneke J.M. Zuetenhorst, Yvonne V. Louwers, Jenny A. Visser, Joop S.E. Laven, Agnes Jager

Get full text

Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study by Niels Heersche, Daan A. C. Lanser, Esther Oomen‐de Hoop, Attila Içli, Peter deBruijn, Marthe S. Paats, Elisabeth F. C. vanRossum, Stijn L. W. Koolen, Ron H. N. vanSchaik, Anne‐Marie C. Dingemans, G. D. Marijn Veerman, Ron H. J. Mathijssen

Get full text

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre... by Niels A.D. Guchelaar, Ron H.J. Mathijssen, Maaike de Boer, Marlies L. van Bekkum, Joan B. Heijns, Birgit E.P.J. Vriens, Mandy M. van Rosmalen, Lonneke W. Kessels, Lisanne Hamming, Karin J. Beelen, Peter Nieboer, Susan M. van den Berg, Esther Oomen-de Hoop, Rhodé M. Bijlsma, Monique E.M.M. Bos

Get full text